Lilly's Favorite Pet Dinosaur Just Hit the Public Markets
TRex Bio just priced a $125 million IPO with Eli Lilly owning nearly a quarter of the company. The autoimmune biotech's approach to immune regulation (and Lilly's unusually deep involvement) tells a bigger story about how big pharma is placing its bets.
Most biotech startups would kill for a single big pharma partner. TRex Bio walked into its IPO with Eli Lilly owning nearly a quarter of the company, a $55 million upfront deal already in the books, and up to $1.1 billion in milestone payments on the table. Not bad for a company named after a dinosaur.
TRex Bio (ticker: TRXB) priced its initial public offering on October 8, 2026, selling 8.33 million shares at a range of $14 to $16 per share. That puts the raise at roughly $125 million at the midpoint, with the potential to stretch to $133 million if shares price at the top. The stock is expected to start trading on the Nasdaq Global Select Market around October 9, with J.P. Morgan, Cantor, Evercore ISI, Stifel, and Wedbush PacGrow running the books.
But the money isn't the most interesting part. The story behind who's backing this company and what it's trying to do is where things get genuinely fascinating.
The Lilly Connection Runs Deep
Calling Lilly a "backer" of TRex Bio is like calling Tom Brady a "participant" in the Super Bowl. It undersells the relationship by a mile.
Lilly currently owns about 23.9% of TRex Bio, according to IPO filings. The pharma giant has also signaled interest in buying shares in the offering itself, though it plans to keep its post-IPO stake at or below 19.9%. That's not passive investor behavior; that's a company keeping its seat at the table while staying just below the threshold that triggers messy regulatory disclosures.
The partnership dates back to a 2023 research and licensing collaboration, where Lilly took rights to three of TRex Bio's immune-regulatory programs. The deal came with $55 million upfront and up to $1.1 billion in milestones. One of those programs, called TRB-051, is now in Lilly's hands and advancing toward a Phase 2a trial in cutaneous lupus.
So Lilly isn't just writing checks. It's actively developing TRex Bio's science in its own clinical pipeline. Think of it like a restaurant investor who also happens to be the head chef: skin in the game hands on the stove.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
and
What TRex Bio Actually Does (Without the Jargon)
The immune system is basically a security team. When it works well, it catches intruders (viruses, bacteria) and leaves your own body alone. In autoimmune diseases like atopic dermatitis (severe eczema) or lupus, that security team goes rogue and starts attacking the building it's supposed to protect.
Most treatments for autoimmune diseases work by suppressing the entire immune system, which is like firing the whole security team because a few guards went haywire. Effective, but you're left unprotected.
TRex Bio takes a different approach. Instead of shutting everything down, the company focuses on tissue regulatory T cells (Tregs), a specialized subset of immune cells whose job is to keep the rest of the immune system in check. Think of Tregs as the shift supervisors who calm down the overzealous guards. TRex Bio's drugs are designed to activate and expand these supervisors right where the inflammation is happening, restoring order without leaving the building defenseless.
The Pipeline: Two Programs, One Big Idea
TRex Bio's lead program is TRB-061, a drug that targets a receptor called TNFR2 to selectively activate Tregs in inflamed tissue. It's currently in a Phase 1a/b clinical trial for moderate-to-severe atopic dermatitis. Behind it sits TRB-071, a CD30-targeting drug designed to both boost Tregs and block inflammatory signals. That one is still in preclinical studies, working toward an IND filing (the application you need before testing a drug in humans).
Neither program is particularly far along, which makes the $125 million raise and Lilly's enthusiasm all the more notable. Investors aren't paying for late-stage data here. They're paying for a platform bet: the idea that TRex Bio's Treg-focused approach could work across multiple autoimmune diseases if the biology holds up.
The IPO Window: Selective, Not Shut
TRex Bio isn't entering a red-hot IPO market. October 2026 has been relatively quiet, with only a handful of biotech debuts on the calendar. But the deals that are getting done look healthy. Across the year, roughly 23 biotech IPOs have raised about $7.4 billion.
The pattern is clear: investors are open for business, but only for companies with strong stories, credible backers, and near-term clinical catalysts. A speculative-stage company with no pharma partner? Tough sell. A Treg-focused autoimmune play backed by Lilly, with a co-founder list that includes immunology heavyweights and a venture syndicate featuring Pfizer Ventures, J&J Innovation, and SV Health Investors? That checks the boxes.
ADARx, another recent biotech IPO, managed to price at the top of its range and upsize its offering, which suggests the market still has appetite for the right names.
Lilly's Bigger Playbook
TRex Bio fits neatly into Lilly's broader 2025–2026 strategy of taking early equity stakes in promising biotechs, then scaling up involvement as the science de-risks. The pharma giant has been busy: an equity-backed deal with Gate Bioscience, plus outright acquisitions of Verve Therapeutics (about $1 billion upfront) and Adverum Biotechnologies.
The strategy resembles a venture capital fund more than a traditional pharma R&D department: place many bets early, double down on winners, and convert partnerships into full ownership when an asset proves itself.
For TRex Bio, that means the IPO might just be the beginning of the relationship, not the culmination.
The Bottom Line
TRex Bio's IPO is a solid mid-size raise for an early-stage autoimmune company. On its own, that's a nice story. What makes it a great story is the strategic depth behind it: Lilly's multi-layered involvement, a differentiated scientific approach that avoids the blunt-force immunosuppression playbook, and a market environment that's rewarding quality over quantity.
The real question isn't whether TRex Bio can raise $125 million (it clearly can). It's whether its Treg platform delivers clinical proof that targeted immune regulation works better than the suppress-everything approach. If TRB-061's atopic dermatitis data reads out well, expect Lilly to tighten its grip. If it doesn't, well, even dinosaurs can go extinct twice.
Clinical & Regulatory
4 min read
The $3.95 Million Drug That Costs More Than Most Houses
Ultragenyx just priced its new gene therapy Fayuvi at $3.95 million per patient, making it the second most expensive drug in the world. It's a one-time treatment for a fatal childhood brain disease with zero alternatives, and it's reigniting the fiercest debate in biotech: who pays for a genetic cure?
